High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment

By Renuka Rayasam on May 21, 2024 for KFF Health News

The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments. Here…

Kaiser Health News is a nonprofit national health polity news service that is part of the nonpartisan Henry J. Kaiser Family Foundation

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.